Barclays Boosts Haleon (NYSE:HLN) Price Target to GBX 364

Haleon (NYSE:HLN – Get Rating) had its target price lifted by Barclays from GBX 360 ($4.45) to GBX 364 ($4.50) in a report issued on Tuesday morning, The Fly reports.

Separately, Morgan Stanley raised shares of Haleon from an equal weight rating to an overweight rating in a research report on Friday, January 6th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus target price of $364.00.

Haleon Price Performance

Shares of HLN opened at $8.08 on Tuesday. The stock has a 50 day simple moving average of $7.76. Haleon has a fifty-two week low of $5.59 and a fifty-two week high of $8.50.

Institutional Investors Weigh In On Haleon

Hedge funds and other institutional investors have recently bought and sold shares of the company. Fifth Third Bancorp purchased a new stake in Haleon during the third quarter valued at approximately $66,000. Gilman Hill Asset Management LLC purchased a new stake in Haleon during the third quarter valued at approximately $426,000. Crossmark Global Holdings Inc. purchased a new stake in Haleon during the third quarter valued at approximately $1,642,000. Janiczek Wealth Management LLC purchased a new position in shares of Haleon in the third quarter worth $83,000. Finally, Stratos Wealth Partners LTD. purchased a new position in shares of Haleon in the third quarter worth $118,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Company Profile

(Get Rating)

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.